These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 17704661)

  • 1. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
    Xiang XJ; Liu YW; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
    Anticancer Drugs; 2012 Jun; 23(5):561-6. PubMed ID: 22481063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Zhao JG; Qiu F; Xiong JP; Zhang L; Xiang XJ; Yu F; Yan J; Zhan ZY; Feng M
    Anticancer Drugs; 2009 Apr; 20(4):281-6. PubMed ID: 19247179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
    Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A
    Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
    Mohammad HA; Magdy FM; Mahmoud OM
    Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
    Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
    J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
    Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
    Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
    Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
    Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.